Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1987 1
2008 2
2009 1
2013 1
2016 1
2019 1
2020 1
2021 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Davis LE, et al. Among authors: livingston mb. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. J Clin Oncol. 2019. PMID: 31013172 Free PMC article. Clinical Trial.
Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.
Jagosky MH, Anderson CJ, Symanowski JT, Steuerwald NM, Farhangfar CJ, Baldrige EA, Benbow JH, Livingston MB, Patt JC, Ahrens WA, Kneisl JS, Kim ES. Jagosky MH, et al. Among authors: livingston mb. Cancer Med. 2023 Mar;12(6):7029-7038. doi: 10.1002/cam4.5502. Epub 2022 Dec 4. Cancer Med. 2023. PMID: 36464833 Free PMC article.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Chawla SP, et al. Among authors: livingston mb. J Clin Oncol. 2022 Apr 20;40(12):1291-1300. doi: 10.1200/JCO.20.03452. Epub 2021 Jul 14. J Clin Oncol. 2022. PMID: 34260265 Clinical Trial.
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. Attia S, et al. Among authors: livingston mb. Cancer Med. 2023 Jan;12(2):1532-1539. doi: 10.1002/cam4.5044. Epub 2022 Aug 10. Cancer Med. 2023. PMID: 35950293 Free PMC article. Clinical Trial.
Characteristics and content of medical library tutorials: a review.
Anderson RP, Wilson SP, Livingston MB, LoCicero AD. Anderson RP, et al. Among authors: livingston mb. J Med Libr Assoc. 2008 Jan;96(1):61-3. doi: 10.3163/1536-5050.96.1.61. J Med Libr Assoc. 2008. PMID: 18219383 Free PMC article. Review. No abstract available.
Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms.
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Manandhar M, Patt JC, Kneisl JS, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. Squires MH, et al. Among authors: livingston mb. Ann Surg Oncol. 2022 May;29(5):3291-3301. doi: 10.1245/s10434-021-11205-5. Epub 2022 Jan 11. Ann Surg Oncol. 2022. PMID: 35015183
A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma.
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Abbott DE, Schwartz P, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. Squires MH, et al. Among authors: livingston mb. J Surg Oncol. 2021 Oct;124(5):829-837. doi: 10.1002/jso.26586. Epub 2021 Jul 13. J Surg Oncol. 2021. PMID: 34254691
Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, Symanowski JT, Steuerwald NM, Anderson CJ, Patt JC, Kneisl JS, Kim ES. Livingston MB, et al. Clin Cancer Res. 2021 Dec 1;27(23):6424-6431. doi: 10.1158/1078-0432.CCR-21-2001. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475102 Clinical Trial.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Meric-Bernstam F, et al. Among authors: livingston mb. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385. JCO Precis Oncol. 2023. PMID: 38096472
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. Riedel RF, et al. Among authors: livingston mb. Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20. Oncologist. 2020. PMID: 32701199 Free PMC article. Clinical Trial.
16 results